The goal is to determine if integration of DCE-MRI and molecular markers improves early prediction of breast cancer response to neoadjuvant chemotherapy (NACT). 49 patients undergoing standard of care NACT had DCE-MRI before and after the first NACT cycle, with 12 of them achieving pathologic complete response (pCR) after NACT. Pharmacokinetic (PK) analysis of DCE-MRI data was performed using the shutter-speed model. Changes in PK parameters were superior to changes in tumor size for early prediction of pCR. The improvement in predictive performance by combining DCE and HR, HER2 molecular markers was statistically significant compared to using MRI markers alone.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords